Allylic and Allenic Halide Synthesis via NbCl<sub>5</sub>- and NbBr<sub>5</sub>-Mediated Alkoxide Rearrangements
作者:P. C. Ravikumar、Lihua Yao、Fraser F. Fleming
DOI:10.1021/jo901287f
日期:2009.10.2
Addition of NbCl5 or NbBr5 to a series of magnesium, lithium, or potassium allylic or propargylic alkoxides directly provides allylic or allenic halides. Halogenation formally occurs through a metalla-halo-[3,3] rearrangement, although concerted, ionic, and direct displacement mechanisms appear to operate competitively. Transposition of the olefin is equally effective for allylic alkoxides prepared
将NbCl 5或 NbBr 5 添加到一系列镁、锂或钾的烯丙基或炔丙基醇盐中直接提供烯丙基或烯丙基卤化物。卤化通过金属-卤-[3,3] 重排正式发生,尽管协同、离子和直接置换机制似乎具有竞争性。烯烃的转位对于通过亲核加成、去质子化或还原制备的烯丙基醇盐同样有效。实验上,五卤化铌卤化反应迅速,萃取后可提供基本纯的 ( E )-烯丙基或烯丙基卤化物,适用于一系列脂肪族和芳香族醇、醛和酮。
Palladium-Catalyzed Reductive Aminocarbonylation of <i>o</i>-Iodophenol-Derived Allyl Ethers with <i>o</i>-Nitrobenzaldehydes to 3-Alkenylquinolin-2(1<i>H</i>)-ones
作者:Jian-Li Liu、Wei Wang、Xinxin Qi、Xiao-Feng Wu
DOI:10.1021/acs.orglett.2c00648
日期:2022.3.25
An attractive palladium-catalyzed reductive aminocarbonylation reaction of allylic ethers has been explored for the synthesis of 3-alkenylquinolin-2(1H)-one derivatives. With Mo(CO)6 as both CO surrogate and reductant, a variety of 3-alkenylquinolin-2(1H)-ones were obtained in good to excellent yields from o-iodophenol-derived allyl ethers with o-nitrobenzaldehydes as the nitrogen sources. This reaction
已经探索了一种有吸引力的钯催化的烯丙基醚的还原氨基羰基化反应,用于合成 3-alkenylquinolin-2(1 H )-one 衍生物。以Mo(CO) 6作为CO 替代物和还原剂,以邻硝基苯甲醛为氮源,由邻碘苯酚衍生的烯丙基醚以良好至优异的收率获得了多种3-alkenylquinolin-2(1 H )-one . 该反应通过级联途径进行,不依赖于以前的烯丙基羰基化反应所需的高压 CO 气体。该策略为构建 3-alkenylquinolin-2(1 H )-ones 提供了新途径。
Organic compounds and their pharmaceutical use
申请人:Lilly Industries Limited
公开号:EP0146333A1
公开(公告)日:1985-06-26
@ There is described compounds of the formula
in which R1 is hydrogen or C1-6alkyl, R2 is hydrogen, C1-6 alkyl or C3-6 alkenyl, and X is -CH = CH- or -(CH2)n- where n is 1 to 3, and Y is -CN or
and salts thereof. The compounds in which Y is tetrazolyl possess pharmaceutical activity.
Novel Inhibitors of Staphyloxanthin Virulence Factor in Comparison with Linezolid and Vancomycin versus Methicillin-Resistant, Linezolid-Resistant, and Vancomycin-Intermediate <i>Staphylococcus aureus</i> Infections in Vivo
Our previous work (Wang et al. J. Med. Chem. 2016, 59, 4831-4848) revealed that effective benzocycloalkane-derived staphyloxanthin inhibitors against methicillin-resistant Staphylococcus aureus (S. aureus) infections were accompanied by poor water solubility and high hERG inhibition and dosages (preadministration). In this study, 92 chroman and coumaran derivatives as novel inhibitors have been addressed for overcoming deficiencies above. Derivatives 69 and 105 displayed excellent pigment inhibitory activities and low hERG inhibition, along with improvement of solubility by salt type selection. The broad and significantly potent antibacterial spectra of 69 and 105 were displayed first with normal administration in the livers and hearts in mice against pigmented S. aureus Newman, Mu50 (vancomycin-intermediate S. aureus), and NRS271 (linezolid-resistant S. aureus), compared with linezolid and vancomycin. In summary, both 69 and 105 have the potential to be developed as good antibacterial candidates targeting virulence factors.
Novel Staphyloxanthin Inhibitors with Improved Potency against Multidrug Resistant <i>Staphylococcus aureus</i>
Diapophytoene desaturase (CrtN) is a potential novel target for intervening in the biosynthesis of the virulence factor staphyloxanthin. In this study, 38 1,4-benzodioxan-derived CrtN inhibitors were designed and synthesized to overwhelm the defects of leading compound 4a. Derivative 47 displayed superior pigment inhibitory activity, better hERG inhibitory properties and water solubility, and significantly sensitized MRSA strains to immune clearance in vitro. Notably, 47 displayed excellent efficacy against pigmented S. aureus Newman, Mu50 (vancomycin-intermediate MRSA, VISA), and NRS271 (linezolid-resistant MRSA, LRSA) comparable to that of linezolid and vancomycin in vivo.